Duloxetine
Product Images NDC 55700-727

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 55700-727). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Quality Care Products, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (New Doc 2019 03 04 09.46.30)

Label for Duloxetine DR 20 mg capsules packaged and distributed by Quality Care Products, LLC. The label indicates 30 capsules per bottle, with each capsule containing enteric-coated pellets equivalent to 20 mg of Duloxetine. The capsules are white and blue. The label includes warnings to keep out of children's reach and storage instructions, along with the NDC number 55700-0727-30 and the product is marketed by Ajanta Pharma USA Inc.*

FDA Label Image

Figure01 (Duloxetine Fig01)

A line graph showing the proportion of patients with relapse over time in days from randomization. The graph compares two treatments: placebo and Duloxetine, with Duloxetine displaying a lower proportion of relapse over the observed period.*

FDA Label Image

Figure2 (Duloxetine Fig02)

A line graph comparing the proportion of patients with relapse over time from randomization (in days) between Duloxetine and placebo treatments. The x-axis shows days up to 300, and the y-axis shows the proportion of patients with relapse ranging from 0.0 to 1.0. Duloxetine is represented by a solid line, and placebo by a dashed line, with placebo showing higher relapse proportions over time.*

FDA Label Image

Figure04 (Duloxetine Fig04)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo, with improvement percentages decreasing as pain improvement increases.*

FDA Label Image

Figure07 (Duloxetine Fig07)

A line graph comparing the percentage of patients improved by duloxetine 60/120 mg once daily versus placebo. The x-axis shows percent improvement in pain from baseline (BOCF) in increments from >0 to 100, and the y-axis shows the percentage of patients improved from 0 to 100. The graph shows higher patient improvement percentages with duloxetine compared to placebo across various pain improvement thresholds.*

FDA Label Image

Figure08 (Duloxetine Fig08)

A line graph comparing the percentage of patients improved between placebo and Duloxetine 60 mg once daily. The x-axis shows the percent improvement in pain from baseline (BOCF) ranging from >0 to 100, while the y-axis indicates the percentage of patients improved from 0 to 100%. Two lines represent placebo and Duloxetine, showing higher improvement percentages in patients taking Duloxetine across most improvement levels.*

FDA Label Image

Figure09 (Duloxetine Fig09)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). Two lines compare placebo to Duloxetine 60/120 mg once daily, illustrating patient improvement differences at various pain improvement thresholds.*

FDA Label Image

Duloxetine-structure (Duloxetine Structure)

Chemical structure of duloxetine hydrochloride, showing its molecular arrangement including a naphthalene group, a thiophene ring, and an amine group as part of its active ingredient structure.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.